Doxorubicin in relapsed soft tissue sarcoma: justification of phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group Study

Eur J Cancer. 1990 Feb;26(2):139-41. doi: 10.1016/0277-5379(90)90296-6.
No abstract available

MeSH terms

  • Adult
  • Doxorubicin / therapeutic use*
  • Drug Evaluation
  • Female
  • Humans
  • Male
  • Middle Aged
  • Sarcoma / drug therapy*
  • Soft Tissue Neoplasms / drug therapy*

Substances

  • Doxorubicin